gptkbp:instanceOf
|
vaccine
viral vector vaccine
|
gptkbp:activeIngredient
|
recombinant, replication-incompetent adenovirus type 26 vector encoding SARS-CoV-2 spike protein
|
gptkbp:administeredBy
|
gptkb:Brazil
gptkb:Canada
gptkb:European_Union
gptkb:South_Africa
gptkb:United_States
adults 18 years and older
|
gptkbp:approvedBy
|
2021-02-27
|
gptkbp:ATCCode
|
gptkb:J07BX03
|
gptkbp:boosterAuthorization
|
gptkb:United_States
|
gptkbp:boosterAuthorizationDate
|
2021-10-20
|
gptkbp:clinicalTrialPhase
|
gptkb:ENSEMBLE_trial
|
gptkbp:containsAdjuvant
|
no
|
gptkbp:countryOfOrigin
|
gptkb:United_States
|
gptkbp:developedBy
|
gptkb:Johnson_&_Johnson
gptkb:Janssen_Pharmaceuticals
|
gptkbp:dosingRegimen
|
single dose
|
gptkbp:efficacyAgainstModerateToSevereCOVID19
|
66%
|
gptkbp:efficacyAgainstSevereCOVID19
|
85%
|
gptkbp:emergencyServices
|
gptkb:European_Union
gptkb:United_States
gptkb:World_Health_Organization
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ad26.COV2.S vaccine
|
gptkbp:includedInCOVAX
|
yes
|
gptkbp:legalStatus
|
gptkb:emergency_use_authorization
conditional marketing authorization
withdrawn in the United States (2023)
|
gptkbp:marketedAs
|
gptkb:Johnson_&_Johnson_COVID-19_Vaccine
gptkb:Janssen_COVID-19_Vaccine
|
gptkbp:notRecommendedFor
|
children under 18
people with history of severe allergic reaction to any component
|
gptkbp:platform
|
adenovirus vector
|
gptkbp:regulatorySuspension
|
United States (April 2021, temporary)
|
gptkbp:regulatorySuspensionReason
|
rare blood clot events
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
gptkbp:shelfLife
|
up to 3 months at 2–8°C
up to 2 years at -20°C
|
gptkbp:sideEffect
|
gptkb:Guillain-Barré_syndrome
fever
fatigue
headache
muscle pain
pain at injection site
thrombosis with thrombocytopenia syndrome
|
gptkbp:storage
|
2–8°C
|
gptkbp:target
|
gptkb:COVID-19
|
gptkbp:UNII
|
Q1Y1J9J8B7
|
gptkbp:WHOEmergencyUseListing
|
2021-03-12
|
gptkbp:bfsParent
|
gptkb:ENSEMBLE_trial
|
gptkbp:bfsLayer
|
7
|